Moma Intelligence Named "2022 Women in Sci-Tech Pioneer" | Oasis Vitality

Recently, China Star Market and the Shanghai Institute of Scientific and Technical Information (ISTIS) jointly launched the "2022 Pioneer Sci-Tech Entrepreneurs" rankings. Following more than four months of data collection, verification, and multi-dimensional scoring, the selection unveiled 97 honorees across four categories: 30 Scientist Entrepreneur Pioneers, 15 Scientist Entrepreneur–Industry Driver Pioneers, 20 Female Sci-Tech Pioneers, and 32 Sci-Tech Elites.

The honorees come primarily from core sci-tech sectors including next-generation information technology, biomedicine, enterprise services, and advanced manufacturing. They focus on cutting-edge domains within their respective tracks, aiming to drive industry advancement and explore new scenarios for translating technological innovation into real-world applications through self-developed products. Among them, Rui Gao, founder of Oasis Capital portfolio company Moma Intelligence, was named to the "2022 Female Sci-Tech Pioneers" list.

In a world of constant change and information overload, Oasis Capital will continue to uphold its "top-down" research methodology, drawing on the experience of ecosystem entrepreneurs to deliver clear signals for the long term. We remain anchored by "demographic structure" and "technological innovation" as our entry points, focusing on technology-enabled services in healthcare and enterprise services, and making long-term investments in the most vital entrepreneurs. Celebrating Vitality. Click "Read More" to view the full rankings.

Oasis Capital is a new-generation venture capital firm in China, dedicated to discovering the country's most vital entrepreneurs over the next decade and growing alongside them to create long-term value. "Celebrating Vitality" is Oasis's vision and mission. This vitality is both the direction of structural transformation in our era and the resilience and evolutionary force of entrepreneurs.

Oasis Capital focuses on early and growth-stage investments, with individual ticket sizes ranging from $3 million to $30 million. We concentrate on technology-enabled services, particularly in healthcare and enterprise services, supporting the upgrade of new services driven by technology in China.